IOVERSOL

Details

Stereochemistry	UNKNOWN
Molecular Formula	C18H24I3N3O9
Molecular Weight	807.1113
Optical Activity	UNSPECIFIED
Defined Stereocenters	0 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I

InChI

InChIKey=AMDBBAQNWSUWGN-UHFFFAOYSA-N

InChI=1S/C18H24I3N3O9/c19-13-11(17(32)22-3-8(29)5-26)14(20)16(24(1-2-25)10(31)7-28)15(21)12(13)18(33)23-4-9(30)6-27/h8-9,25-30H,1-7H2,(H,22,32)(H,23,33)

HIDE SMILES / InChI

Molecular Formula	C18H24I3N3O9
Molecular Weight	807.1113
Charge	0
Count

Stereochemistry	MIXED
Additional Stereochemistry	No
Defined Stereocenters	0 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019710s052,020923s018lbl.pdf
Curator's Comment: Description was created based on several sources, including: http://www.drugbank.ca/drugs/DB09134 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=549d38db-d4ed-4708-8f76-7cdaa157063f

Ioversol is an organoiodine compound that used as a contrast medium. It features both a high iodine content, as well as several hydrophilic groups. It is indicated in adults for peripheral and coronary arteriography and left ventriculography, for excretory urography and computed tomography. Injections of contrast media are often associated with sensations of warmth and pain. Renal toxicity has been reported in a few patients with liver dysfunction who were given oral cholecystographic agents followed by intravascular contrast agents.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
vessels and anatomical structures 3 Target ID: vessels and anatomical structures Sources: http://cursoenarm.net/UPTODATE/contents/mobipreview.htm?7/48/7950?source=see_link	Activator 1447

Conditions

Condition	Modality	Highest Phase	Product
Cardiovascular diseases 72 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019710s052,020923s018lbl.pdf	Diagnostic	Approved 8583	OPTIRAY 320 Approved Use Optiray 320 is indicated in adults for angiography throughout the cardiovascular system. The uses include cerebral, coronary, peripheral, visceral and renal arteriography, venography, aortography, and left ventriculography. Optiray 320 is also indicated for contrast enhanced computed tomographic imaging of the head and body, and intravenous excretory urography. Optiray 320 is indicated in children for angiocardiography, contrast enhanced computed tomographic imaging of the head and body, and intravenous excretory urography. Optiray 300 is indicated for cerebral angiography and peripheral arteriography. Optiray 300 is also indicated for contrast enhanced computed tomographic imaging of the head and body, venography, and intravenous excretory urography. Optiray 240 is indicated for cerebral angiography and venography. Optiray 240 is also indicated for contrast enhanced computed tomographic imaging of the head and body and intravenous excretory urography. Launch Date 1988
Urinary system disease 13 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019710s052,020923s018lbl.pdf	Diagnostic	Approved 8583	OPTIRAY 320 Approved Use Optiray 320 is indicated in adults for angiography throughout the cardiovascular system. The uses include cerebral, coronary, peripheral, visceral and renal arteriography, venography, aortography, and left ventriculography. Optiray 320 is also indicated for contrast enhanced computed tomographic imaging of the head and body, and intravenous excretory urography. Optiray 320 is indicated in children for angiocardiography, contrast enhanced computed tomographic imaging of the head and body, and intravenous excretory urography. Optiray 300 is indicated for cerebral angiography and peripheral arteriography. Optiray 300 is also indicated for contrast enhanced computed tomographic imaging of the head and body, venography, and intravenous excretory urography. Optiray 240 is indicated for cerebral angiography and venography. Optiray 240 is also indicated for contrast enhanced computed tomographic imaging of the head and body and intravenous excretory urography. Launch Date 1988
Glioma 25 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019710s052,020923s018lbl.pdf	Diagnostic	Approved 8583	OPTIRAY 320 Approved Use Optiray 320 is indicated in adults for angiography throughout the cardiovascular system. The uses include cerebral, coronary, peripheral, visceral and renal arteriography, venography, aortography, and left ventriculography. Optiray 320 is also indicated for contrast enhanced computed tomographic imaging of the head and body, and intravenous excretory urography. Optiray 320 is indicated in children for angiocardiography, contrast enhanced computed tomographic imaging of the head and body, and intravenous excretory urography. Optiray 300 is indicated for cerebral angiography and peripheral arteriography. Optiray 300 is also indicated for contrast enhanced computed tomographic imaging of the head and body, venography, and intravenous excretory urography. Optiray 240 is indicated for cerebral angiography and venography. Optiray 240 is also indicated for contrast enhanced computed tomographic imaging of the head and body and intravenous excretory urography. Launch Date 1988

C_max

Value	Dose	Co-administered	Analyte	Population
1.45 mg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2793391	50 mL single, intravenous dose: 50 mL route of administration: Intravenous experiment type: SINGLE co-administered:		HYDROGEN IODIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.36 mg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2793391	150 mL single, intravenous dose: 150 mL route of administration: Intravenous experiment type: SINGLE co-administered:		HYDROGEN IODIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
1.74 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2793391	50 mL single, intravenous dose: 50 mL route of administration: Intravenous experiment type: SINGLE co-administered:		HYDROGEN IODIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.43 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2793391	150 mL single, intravenous dose: 150 mL route of administration: Intravenous experiment type: SINGLE co-administered:		HYDROGEN IODIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.06 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2793391	50 mL single, intravenous dose: 50 mL route of administration: Intravenous experiment type: SINGLE co-administered:		HYDROGEN IODIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.04 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2793391	150 mL single, intravenous dose: 150 mL route of administration: Intravenous experiment type: SINGLE co-administered:		HYDROGEN IODIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
100% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019710s054,020923s019lbl.pdf			IOVERSOL plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
1.6 mg/kg 1 times / day single, intravenous Recommended Dose: 1.6 mg/kg, 1 times / day Route: intravenous Route: single Dose: 1.6 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2687200/	unknown, 56 (15-86) Health Status: unknown Age Group: 56 (15-86) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/2687200/	Other AEs: Angina... Other AEs: Angina Sources: https://pubmed.ncbi.nlm.nih.gov/2687200/

AEs

AE	Significance	Dose	Population
Angina		1.6 mg/kg 1 times / day single, intravenous Recommended Dose: 1.6 mg/kg, 1 times / day Route: intravenous Route: single Dose: 1.6 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2687200/	unknown, 56 (15-86) Health Status: unknown Age Group: 56 (15-86) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/2687200/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP 303

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP 303	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020923s026lbl.pdf#page=15 Page: 15.0	no

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY576850	https://www.001chemical.com/chem/87771-40-2
3B Scientific (Wuhan) Corp	3B2-1453	http://www.3bsc.com/index/pro_info.php?id=55169
AA Blocks	AA004LA3	https://www.aablocks.com/goods/Goods/detail?id=AA004LA3
Achemtek	0104-007219	http://www.achemtek.com/87771-40-2
AHH Chemical co.,ltd	MT-52846	http://www.ahhchemical.com/product/MT-52846.html
AK Scientific, Inc. (AKSCI)	71363	http://www.aksci.com/item_detail.php?cat=71363
Alfa Chemistry	87771-40-2	https://www.alfa-chemistry.com/cas_87771-40-2.htm
Alfa Chemistry	AP87771402	https://reagents.alfa-chemistry.com/product/ioversol-cas-87771-40-2-17707.html
Angene	AGN-PC-0BI1NV	http://www.angenechemical.com/productshow/AGN-PC-0BI1NV.html
Aurora Fine Chemicals LLC	A24.076.488	http://online.aurorafinechemicals.com/info?ID=A24.076.488
AvaChem Scientific	3828	http://www.avachem.com/productSearch.asp?3828
BioChemPartner	BCP11109	http://www.biochempartner.com/87771-40-2-BCP11109
BioSynth	Q-201247	https://www.biosynth.com/en/products/life-science/other-biochemicals/products/Q-201247.html
BLD Pharm	BD134819	http://www.bldpharm.com/products/87771-40-2.html
Boerchem	BC215938	http://www.boerchem.com/?product_36614.html
Chem Scene	CS-7483	http://www.chemscene.com/87771-40-2.html
ChemFish Tokyo co.,ltd	3741	http://www.chemfish.co.jp/index.php?id=4618&project=product
ChemMol	30107629	http://www.chemmol.com/chemmol/30107629.html
ChemMol	44005431	http://www.chemmol.com/chemmol/44005431.html
ChemMol	49409497	http://www.chemmol.com/chemmol/49409497.html
Chemspace	CSSB00020618400	https://chem-space.com/CSSB00020618400
Clearsynth	CS-T-56767	https://www.clearsynth.com/en/CST56767.html
Combi-Blocks	QA-1890	http://www.combi-blocks.com/cgi-bin/find.cgi?QA-1890
CSNpharm	CSN21691	https://www.csnpharm.com/products/ioversol.html
Finetech	FT-0627284	http://www.finetechnology-ind.com/prod/detail/pub/87771-40-2.html
Hairui	HR132940	http://www.hairuichem.com/en/product/87771-40-2.html
iChemical	EBD26632	http://www.ichemical.com/products/87771-40-2.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
Infinium PharmaChem Pvt Ltd	CatId-124	http://infiniumpharmachem.com/products/ioversol/
Iodochem	ID10099	https://www.iodochem.com/product/87771-40-2
Lab Network	LN01286620	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01286620
MedChem Express	HY-B1410	https://www.medchemexpress.com/Ioversol.html
Molcore	MC576850	https://www.molcore.com/product/87771-40-2
MuseChem	R012692	https://www.musechem.com/product/R012692.html
OChem	6084	http://www.ocheminc.com/index.php?act=psearch&pid=771I402
Parchem	88088	https://www.parchem.com/chemical-supplier-distributor/Ioversol-088088.aspx
THE BioTek	bt-460576	https://www.thebiotek.com/product/others/bt-460576
Yuhao Chemical	RT1905	http://www.chemyuhao.com/87771-40-2.html

PubMed

Title	Date	PubMed
Opacification of urinary bladder and ureter at CT urography: effect of a log-rolling procedure and postvoiding residual bladder urine volume.	2008-06	18413887
Direct MR arthrography at 1.5 and 3.0 T: signal dependence on gadolinium and iodine concentrations--phantom study.	2008-06	18403628
4D-CT imaging with synchronized intravenous contrast injection to improve delineation of liver tumors for treatment planning.	2008-06	18194819
Detection of biliary duct narrowing and choledocholithiasis: accuracy of portal venous phase multidetector CT.	2008-05	18372450
Utility of contrast-enhanced endoscopic ultrasonography for diagnosis of small pancreatic carcinomas.	2008-04	18045768
A simple method to estimate the optimum iodine concentration of contrast material through microcatheters: hydrodynamic calculation with spreadsheet software.	2008-03-07	18296768
Multidetector-row computed tomography (CT) of blunt pancreatic injuries: can contrast-enhanced multiphasic CT detect pancreatic duct injuries?	2008-03	18332806
Incidence of ventricular fibrillation during left coronary arteriography in pigs: comparison of a solution of the nonionic dimer iodixanol with solutions of five different nonionic monomers.	2008-03	18300138
Adequacy of an early arterial phase low-volume contrast protocol in 64-detector computed tomography angiography for aortoiliac aneurysms.	2008-03	18295101
Contrast enhancement in cardiovascular MDCT: effect of body weight, height, body surface area, body mass index, and obesity.	2008-03	18287452
A dual contrast injection technique for multidetector computed tomography angiography of Fontan procedures.	2008-03	17823851
The fate of infrarenal abdominal aortic aneurysms after stent grafting: influence of thrombosis at side branch ostia.	2008-02-28	18303295
Lymph node enlargement in pulmonary arterial hypertension due to chronic thromboembolism.	2008-02	18373821
Transient homogeneously enhancing hepatic masses: can size predict benignity?	2008-02	18212213
Asialoerythropoietin prevents contrast-induced nephropathy.	2008-02	18184858
ECG-gated chest CT angiography with 64-MDCT and tri-phasic IV contrast administration regimen in patients with acute non-specific chest pain.	2008-02	17763855
Comparative rheology of low- and iso-osmolarity contrast agents at different temperatures.	2008-01-01	18098191
Is hand injection of central venous catheters for contrast-enhanced CT safe in children?	2007-12	18029896
NGAL is an early predictive biomarker of contrast-induced nephropathy in children.	2007-12	17874137
Fatal anaphylactoid reaction following ioversol administration.	2007-12	17557212
Quantification and detectability of in-stent stenosis with CT angiography and MR angiography in arterial stents in vitro.	2007-11	17954666
Spectrum of biliary abnormalities in hepatic hereditary hemorrhagic telangiectasia: demonstration by multidetector computed tomography.	2007-11	17453259
Definitive exclusion of biliary atresia in infants with cholestatic jaundice: the role of percutaneous cholecysto-cholangiography.	2007-09	17605021
Triphasic dynamic CT findings of 63 hepatic focal nodular hyperplasia in 46 patients: correlation with size and pathological findings.	2007-07-17	17632749
[What we can learn from a case of medical malpractice--a case of anaphylactoid shock after administration of nonionic contrast medium].	2007-07	17665563
64 MDCT in multiple trauma patients: imaging manifestations and clinical implications of active extravasation.	2007-07	17483969
Another case of transplacental passage of the non-ionic contrast agent ioversol.	2007-07	17476497
Infection scintigraphy: added value of single-photon emission computed tomography/computed tomography fusion compared with traditional analysis.	2007-06-01	17538282
Peritoneography in the diagnosis of peritoneal leaks in peritoneal dialysis.	2007-04	17406054
Transplacental passage of non-ionic contrast agents resulting in fetal bowel opacification: a mimic of pneumoperitoneum in the newborn.	2007-04	17323055
Modified scan protocol using multislice CT coronary angiography allows high quality acquisitions in obese patients: a case report.	2007-04	16821120
Effect of patient weight and scanning duration on contrast enhancement during pulmonary multidetector CT angiography.	2007-02	17255426
Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in children with chronic kidney disease.	2007-01	17072653
Effect on bone induction of using contrast media to reconstitute recombinant human bone morphogenetic protein-2 in an ectopic model in rats.	2006-11	17120893
Drug eruption caused by the nonionic contrast medium iohexol. "Recall-like phenomenon" appearing on an area previously affected by herpes zoster.	2006-10	17040501
Irbesartan attenuates contrast media-induced NRK-52E cells apoptosis.	2006-10	16828304
A simple radiological technique for demonstration of incorrect positioning of a foley catheter with balloon inflated in the urethra of a male spinal cord injury patient.	2006-06-20	17619716
Drug eruptions to contrast media in Japan.	2006-05	16681576
The prevention of anaphylactoid reactions to iodinated radiological contrast media: a systematic review.	2006-04-27	16643668
Voxel-based mouse and rat models for internal dose calculations.	2006-04	16595500
Lung cancer detected in patients presenting to the Emergency Department studies for suspected pulmonary embolism on computed tomography pulmonary angiography.	2006-04	16377113
Multi-slice CT angiography for arterial evaluation in the injured lower extremity.	2006-03	16531846
Comparative study of vascular enhancement on post-contrast CT using three dosages of iodinated contrast media for the aim of detecting brain metastasis in patients with lung cancer.	2006-02	16715674
Renal function and cardiac angiography.	2006-01	16444061
Involvement of de novo ceramide synthesis in radiocontrast-induced renal tubular cell injury.	2006-01	16408118
Contrast enhancement in electron beam tomography of the heart: comparison of a monomeric and a dimeric iodinated contrast agent in 59 patients.	2006-01	16399037
CT-guided jejunostomy tube insertion.	2005-11	16247172
Small-bowel perfusion measurement: feasibility with single-compartment kinetic model applied to dynamic contrast-enhanced CT.	2005-11	16244275
Quantitative computed tomography perfusion of prostate cancer: correlation with whole-mount pathology.	2005-09	16197611
Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy.	2005-06-15	16465578

Patents

Sample Use Guides

In Vivo Use Guide

Optiray (ioversol injection) 240, Optiray 300 or Optiray 320 is recommended for cerebral arteriography. The usual individual injection for visualization of the carotid or vertebral arteries is 2 to 12 mL. Aortic arch injection for a simultaneous four vessel study requires 20 to 50 mL. Total procedural doses should not usually exceed 200 mL. Optiray 300, Optiray 320 or Optiray 350 is recommended for peripheral arteriography. The dosage is 20-60 ml. Optiray 320 or Optiray 350 is recommended for coronary arteriography. The dosage is 6-40 mL. Optiray 320 is recommended for visceral arteriography, renal arteriography, and aortography procedures. The dosage is 9-45 mL. Optiray 240, Optiray 300, Optiray 320 or Optiray 350 is recommended for venography. The usual dose is 50 to 100 mL per extremity with smaller or larger volumes indicated in some cases. Dosage should not usually exceed 250 mL.

Route of Administration: Intravascular

In Vitro Use Guide

Ioversol 320 mgI/mL did not significantly inhibit clot lysis (14.9+/-11.5% decrease vs. control; p>0.3).

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:23:59 GMT 2025` Edited by `admin` on `Mon Mar 31 18:23:59 GMT 2025`
Record UNII	N3RIB7X24K
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

IOVERSOL

Official Name

English

OPTIRAY

Preferred Name

English

IOVERSOL [JAN]

Common Name

English

N,N'-BIS(2,3-DIHYDROXYPROPYL)-5-(N-(2-HYDROXYETHYL)GLYCOLAMIDO)-2,4,6-TRIIODOISOPHTHALAMIDE

Systematic Name

English

MP 328

Code

English

IOVERSOL [VANDF]

Common Name

English

IOVERSOL [MI]

Common Name

English

IOVERSOL [MART.]

Common Name

English

IOVERSOL [ORANGE BOOK]

Common Name

English

1,3-BENZENEDICARBOXAMIDE, N,N'-BIS(2,3-DIHYDROXYPROPYL)-5-((HYDROXYACETYL)(2-HYDROXYETHYL)AMINO)-2,4,6-TRIIODO-

Systematic Name

English

IOVERSOL [USAN]

Common Name

English

Ioversol [WHO-DD]

Common Name

English

MP-328

Code

English

IOVERSOL [USP-RS]

Common Name

English

ioversol [INN]

Common Name

English

IOVERSOL [USP MONOGRAPH]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QV08AB07